A tubulin binding peptide targets glioma cells disrupting their microtubules, blocking migration, and inducing apoptosis

Molecular Therapy

Volumn 20, Issue 7, 2012, Pages 1367-1377

  Berges, Raphael ^a   Balzeau, Julien ^a   Peterson, Alan C ^a   Eyer, Joël ^a  

^a UNIVERSITÉ D'ANGERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROFILAMENT LIGHT PROTEIN; NEUROFILAMENT PROTEIN; SYNTHETIC PEPTIDE; TUBULIN BINDING PEPTIDE[40-63]; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; BINDING SITE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG TARGETING; DRUG UPTAKE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MICROTUBULE; MIGRATION INHIBITION; NONHUMAN; PEPTIDE ANALYSIS; PROTEIN BINDING;

EID: 84863426056     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.45     Document Type: Article

References (39)

1. Westphal, M, Hilt, DC, Bortey, E, Delavault, P, Olivares, R, Warnke, PC et al. (2003). A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 5: 79-88. (Pubitemid 36422560)
2. Stupp, R, Mason, WP, van den Bent, MJ, Weller, M, Fisher, B, Taphoorn, MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. (Pubitemid 40349501)
3. Katsetos, CD, Dráberová, E, Smejkalová, B, Reddy, G, Bertrand, L, de Chadarévian, JP et al. (2007). Class III beta-tubulin and gamma-tubulin are co-expressed and form complexes in human glioblastoma cells. Neurochem Res 32: 1387-1398. (Pubitemid 46988201)
4. Collet, B, Guitton, N, Saïkali, S, Avril, T, Pineau, C, Hamlat, A et al. (2011). Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach. Proteome Sci 9: 16.
5. Rowinsky, EK (1997). The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 48: 353-374. (Pubitemid 27101837)
6. Schiller, JH (1998). Role of taxanes in lung-cancer chemotherapy. Cancer Invest 16: 471-477. (Pubitemid 28464856)
7. Schrijvers, D and Vermorken, JB (1998). Update on the taxoids and other new agents in head and neck cancer therapy. Curr Opin Oncol 10: 233-241. (Pubitemid 28256929)
8. Wiseman, LR and Spencer, CM (1998). Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. Drugs Aging 12: 305-334. (Pubitemid 28181670)
9. Budman, DR (1997). Vinorelbine (Navelbine): a third-generation vinca alkaloid. Cancer Invest 15: 475-490. (Pubitemid 27439234)
10. Jordan, MA and Wilson, L (1998). Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 10: 123-130. (Pubitemid 28066130)
11. Mollinedo, F and Gajate, C (2003). Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 8: 413-450. (Pubitemid 37247987)
12. Dumontet, C and Sikic, BI (1999). Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17: 1061-1070. (Pubitemid 29109340)
13. Giannakakou, P, Sackett, DL, Kang, YK, Zhan, Z, Buters, JT, Fojo, T et al. (1997). Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272: 17118-17125. (Pubitemid 27289821)
14. Kavallaris, M, Tait, AS, Walsh, BJ, He, L, Horwitz, SB, Norris, MD et al. (2001). Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res 61: 5803-5809. (Pubitemid 32769098)
15. Holland, JF, Scharlau, C, Gailani, S, Krant, MJ, Olson, KB, Horton, J et al. (1973). Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res 33: 1258-1264.
16. Hussain, M, Wozniak, AJ and Edelstein, MB (1993). Neurotoxicity of antineoplastic agents. Crit Rev Oncol Hematol 14: 61-75. (Pubitemid 23183739)
17. Martin, V (1993). Overview of paclitaxel (TAXOL). Semin Oncol Nurs 9(4 Suppl 2): 2-5.
18. Cavaletti, G, Cavalletti, E, Montaguti, P, Oggioni, N, De Negri, O and Tredici, G (1997). Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology 18: 137-145.
19. Windebank, AJ (1999). Chemotherapeutic neuropathy. Curr Opin Neurol 12: 565-571. (Pubitemid 30028616)
20. Bocquet, A, Berges, R, Frank, R, Robert, P, Peterson, AC and Eyer, J (2009). Neurofilaments bind tubulin and modulate its polymerization. J Neurosci 29: 11043-11054.
21. Richard, JP, Melikov, K, Vives, E, Ramos, C, Verbeure, B, Gait, MJ et al. (2003). Cellpenetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 278: 585-590. (Pubitemid 36043612)
22. Stojiljkovic, M, Piperski, V, Dacevic, M, Rakic, L, Ruzdijic, S and Kanazir, S (2003). Characterization of 9L glioma model of the Wistar rat. J Neurooncol 63: 1-7. (Pubitemid 36681636)
23. Van Meir, EG (2009). CNS cancer: models, markers, prognostic factors, targets, and therapeutic approaches.
24. Els, T, Eis, M, Hoehn-Berlage, M and Hossmann, KA (1995). Diffusion-weighted MR imaging of experimental brain tumors in rats. MAGMA 3: 13-20.
25. Wang, TH, Wang, HS and Soong, YK (2000). Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 88: 2619-2628.
26. Terzis, A-J, Thorsen, F, Heesel, O, Visted, T, Bjerkvig, R, Dahl, O et al. (1997) Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. Br J Cancer 75: 1744-1752. (Pubitemid 27230698)
27. Panopoulos, A, Howell, M, Fotedar, R and Margolis, RL (2011). Glioblastoma motility occurs in the absence of actin polymer. Mol Biol Cell 22: 2212-2220.
28. Balzeau, J, Peterson, A and Eyer, J (2012). The vimentin-tubulin binding site peptide (Vim-TBS.58-81) crosses the plasma membrane and enters the nuclei of human glioma cells. Int J Pharm 423: 77-83.
29. Shadidi, M and Sioud, M (2003). Selective targeting of cancer cells using synthetic peptides. Drug Resist Updat 6: 363-371. (Pubitemid 38173587)
30. Shadidi, M and Sioud, M (2003). Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells. FASEB J 17: 256-258.
31. Ho, IA, Lam, PY and Hui, KM (2004). Identification and characterization of novel human glioma-specific peptides to potentiate tumor-specific gene delivery. Hum Gene Ther 15: 719-732. (Pubitemid 39095245)
32. Wu, C, Lo, SL, Boulaire, J, Hong, ML, Beh, HM, Leung, DS et al. (2008). A peptidebased carrier for intracellular delivery of proteins into malignant glial cells in vitro. J Control Release 130: 140-145
33. McCarthy, KD and de Vellis, J (1980). Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85: 890-902. (Pubitemid 10007455)
34. Ray, J, Peterson, DA, Schinstine, M and Gage, FH (1993). Proliferation, differentiation, and long-term culture of primary hippocampal neurons. Proc Natl Acad Sci USA 90: 3602-3606. (Pubitemid 23111415)
35. Kaech, S and Banker, G (2006). Culturing hippocampal neurons. Nat Protoc 1: 2406-2415.
36. Terzis, AJ, Thorsen, F, Heese, O, Visted, T, Bjerkvig, R, Dahl, O et al. (1997). Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. Br J Cancer 75: 1744-1752. (Pubitemid 27230698)
37. Redgate, ES, Deutsch, M and Boggs, SS (1991). Time of death of CNS tumor-bearing rats can be reliably predicted by body weight-loss patterns. Lab Anim Sci 41: 269-273.
38. Jing, R, Pizzolato, G, Robson, RM, Gabbiani, G and Skalli, O (2005). Intermediate filament protein synemin is present in human reactive and malignant astrocytes and associates with ruffled membranes in astrocytoma cells. Glia 50: 107-120. (Pubitemid 40695265)
39. Mathieu, D, Lecomte, R, Tsanaclis, AM, Larouche, A and Fortin, D (2007). Standardization and detailed characterization of the syngeneic Fischer/F98 glioma model. Can J Neurol Sci 34: 296-306. (Pubitemid 47359832)